SCHEMBL25547142

SCHEMBL25547142

Cc1ccc(CNS(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.83

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.83
CYP1A2 P05177 1/20 0.83
CYP3A4 P08684 1/20 0.83
ATM Q13315 1/20 0.83
CA9 Q16790 1/20 0.83
L3MBTL1 Q9Y468 1/20 0.83
ALDH1A1 P00352 7/20 0.78
LMNA P02545 4/20 0.77
SMN1; SMN2 Q16637 2/20 0.77
HTT P42858 1/20 0.77
CYP19A1 P11511 1/20 0.74
CNR2 P34972 1/20 0.73
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
TP53 P04637 1/20 0.64
KDM4E B2RXH2 1/20 0.63
HPGD P15428 2/20 0.62
USP2 O75604 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17827613 0.93 CA12 (0.73) CA12CYP1A2CYP3A4ATMCA9
SCHEMBL28113725 0.91 CA12 (0.73) CA12CYP1A2CYP3A4ATMCA9
SCHEMBL26154030 0.91 CA12 (0.71) CA12CYP1A2CYP3A4ATMCA9
SCHEMBL5960116 0.91 MEN1 (0.73) CA12CYP1A2CYP3A4ATMCA9
SCHEMBL5960052 0.91 CA12 (0.71) CA12CYP1A2CYP3A4ATMCA9
SCHEMBL3925035 0.91 CA12 (0.71) CA12CYP1A2CYP3A4ATMCA9
SCHEMBL27950177 0.91 CA12 (0.71) CA12CYP1A2CYP3A4ATMCA9
SCHEMBL27950175 0.91 CA9 (0.71) CA12CYP1A2CYP3A4ATMCA9
SCHEMBL4662819 0.91 CA12 (0.87) CA12CYP1A2CYP3A4ATMCA9
SCHEMBL198318 0.91 CA12 (1.00) CA12CYP1A2CYP3A4ATMCA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250109098-A1 METHOD FOR PREPARING BENZYLAMINE DERIVATIVE THROUGH AMINATION OF BENZYLIC C-H BOND UNDER VISIBLE LIGHT-INDUCED NICKEL CATALYSIS SHANGHAI OURCHEM BIO-TECHNOLOGY CO., LTD. (CN) 2025-04-03 US disclosed
WO-2024164666-A1 METHOD FOR PREPARING BENZYLAMINE DERIVATIVE BY VISIBLE LIGHT-PROMOTED NICKEL-CATALYZED AMINATION OF BENZYL C-H BONDS 上海沃凯生物技术有限公司 2024-08-15 WO disclosed
CN-116063209-B Method for preparing benzylamine derivative by catalyzing amination of benzyl C-H bond through nickel under promotion of visible light 上海沃凯生物技术有限公司 2024-04-09 CN disclosed
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 US disclosed
US-20230159469-A1 NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF TXINNO BIOSCIENCE INC. (KR) 2023-05-25 US disclosed
CN-116063209-A Method for preparing benzylamine derivative by catalyzing amination of benzyl C-H bond through nickel under promotion of visible light 上海沃凯生物技术有限公司 2023-05-05 CN disclosed
CN-112047865-B Method for synthesizing N-alkyl sulfonamide in water 南京理工大学 2022-12-02 CN disclosed
CN-112047865-A Method for synthesizing N-alkyl sulfonamide in water 南京理工大学 2020-12-08 CN disclosed
CN-104418678-B A kind of method of synthetic N-alkyl sulfonamide derivatives NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2016-05-18 CN disclosed
CN-104418678-A Method for synthesizing N-alkyl sulfonamide derivative UNIV NANJING SCIENCE & TECH 2015-03-18 CN disclosed
CN-103553978-A Sulfamide benzylation method UNIV CHONGQING 2014-02-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF SSB, EBNA1BP2, PML CA12 3663/4885CYP1A2 4750/4885CYP3A4 4532/4885
US-20250109098-A1 METHOD FOR PREPARING BENZYLAMINE DERIVATIVE THROUGH AMINATION OF BENZYLIC C-H BOND UNDER VISIBLE LIGHT-INDUCED NICKEL CATALYSIS HRH3, HRH4, HRH2 CA12 2011/4885CYP1A2 1806/4885CYP3A4 1539/4885
US-20230159469-A1 NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF ENPP1, ENPP3, PPA1 CA12 3292/4885CYP1A2 4589/4885CYP3A4 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.